Furthermore, the use of a point-of-care CRP level >40 mg/dL significantly increases the predictive accuracy of treatment failure among patients with exacerbated mild to moderate chronic obstructive pulmonary disease [20, 21]. This evidence concerns the gene CRP and chronic obstructive pulmonary disease.